UMN Pharma Inc. today announced that it has secured an additional investment of roughly $2 million as part of an existing construction agreement with IHI Plant Engineering Corporation (headquartered in Tokyo, hereinafter referred to as "IPEC"), an affiliate of IHI Corporation. The investment was triggered by successful UMN-0501 Phase I/II study results that met certain predetermined criteria. UMN Pharma believes that this funding will serve to further strengthen the collaboration with IPEC.